ABSTRACT
Background Non-melanoma skin cancer (NMSC) is the most prevalent cancer in the United States. Despite guidelines on UV radiation avoidance, it remains difficult for people to assess their individual exposure, as UV is invisible and the onset of UV-induced symptoms is delayed.
Objective To measure the clincal impact of a wearable UV dosimeter that provides real-time information to users.
Methods In a prospective randomised trial, ninety-seven elderly patients with a history of actinic keratoses (AK) were enrolled and followed over six months. Fifty patients were given a wearable UV dosimeter that provided real-time and cumulative daily UV exposure, and forty-seven patients received UV protection counseling by a dermatologist.
Results After 6 months of intervention, when comparing the device group to the control group, we observed a 20% lower ratio of incidence rates of AKs (95% CI = [-41%, 55%], p-value = 0.44) and a 95% lower ratio of incidence rates of NMSCs (95% CI = [33%, 99.6%], p-value = 0.024).
Limitations The study has a short duration and a small sample size.
Conclusion This pilot clinical trial suggests that providing real-time UV exposure data using a wearable UV dosimeter may assist in the reduction of NMSC in an elderly population.
Competing Interest Statement
Peter Kaplan and Emmanuel Dumont are employees of Shade. Peter Kaplan, Emmanuel Dumont, and Jonathan Zippin are shareholders of Shade.
Clinical Trial
NCT03315286
Funding Statement
Funded by the National Cancer Institute, contract HHSN261201700005C
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Weill-Cornell Medicine gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: National Cancer Institute, contract HHSN261201700005C.
Conflicts of Interest: Emmanuel Dumont and Peter Kaplan are employees of Shade. Emmanuel Dumont, Peter Kaplan, Jonathan Zippin are shareholders of Shade.
IRB. This trial was approved by the IRB of Weill-Cornell Medicine.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
ABBREVIATIONS
- AK
- Actinic Keratosis
- BCC
- Basal Cell Carcinoma
- CI
- Confidence Interval
- CRF
- Case Report Form
- IR
- Incidence Rate
- IRB
- Institutional Review Board
- IRR
- Incidence Rate Ratio
- NCI
- National Cancer Institute
- NIH
- National Institute of Healths
- NMSC
- Non-Melanoma Skin Cancer
- PROMIS
- Patient-Reported Outcomes Measurement Information System
- SCC
- Squamous Cell Carcinoma
- SD
- Standard Deviation
- SED
- Standard Erythema Dose
- UV
- Ultraviolet
- UVI
- UV Index
- UVR
- Ultraviolet Radiation